Dr. Diana Dupont-Roettger will speak at Immuno Oncology 360˚

Dr. Diana Dupont-Roettger will be speaking at Immuno Oncology 360˚

Traditional trial designs and endpoints are no longer suited for the fast-changing clinical Immuno-Oncology (IO) development. The methodologies and design of cancer clinical trials are under profound changes: Umbrella, basket, or platform designs, all create a unique opportunity to drive collaboration, coordination, and accelerated innovation. Non-invasive imaging biomarkers can have a unique contribution by helping to understand the underlying biology behind various cancers. Amongst other biomarkers, they create the hope of a more focused and personalized medicine, which has the potential to bring more efficient and tailored treatments to patients.

Dr. Diana Dupont-Roettger will be speaking at the Immuno-Oncology 360˚ (IO360) conference during the IO Novel Technologies session on Thursday 27 February. Her talk entitled ‘Advanced Imaging Markers for IO Drug Development’, outlines the potential of imaging markers derived from advanced imaging methodologies, Artificial Intelligence (AI) and Quantitative Imaging to advance IO treatments. Case studies highlighted the role of novel prognostic, predictive, and response imaging markers.

The scope of discussions for this conference includes:
– Understanding Pseudo-Progression through quantification of changes in the tumour microenvironment
– Machine Learning for non-invasive Imaging Phenotyping
– Machine Learning in Digital Pathology
– Predicting immunotherapy response through advanced imaging marker
– IAG’s proprietary cloud technology that supports umbrella, basket, or platform designs to create a unique opportunity to drive collaboration, coordination, and accelerated innovation in the IO field

About Dr. Diana Dupont-Roettger:
Diana is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers as well as their role for biotech and pharma. She is an expert in scientific imaging clinical trial design and advises biotech and pharma on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.

About IAG:
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

About IO360˚:
IO360˚convenes stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.
To find out more about this conference click here.

News
Events